Abstract
This short review focuses on the role of hematopoietic SCT (HSCT) in childhood AML. In first CR (CR1), some studies demonstrate superiority of allogeneic HSCT with HLA identical sibling donors over the continuation of chemotherapy and others did not. The studies differ in regard to the included risk categories of patients and the outcome niveau of the chemotherapy arm. The BFM98 study found no benefit in having a donor, in particular in terms of overall survival. Autologous HSCT in CR1 is not superior in any of the reviewed trials over the continuation of chemotherapy. In second CR, evidence for the function of allogeneic HSCT is small. However, published data and evidence-based reports recommend an unrelated or related transplantation in the situation of a renewed remission. Data on haploidentical HSCT and on cord blood HSCT are still lacking in the case of AML. Combined studies of larger study groups are warranted to broaden the data basis for rational decision.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2007; 13: 1–25.
Ortega JJ, Diaz de Heredia C, Olive T, Bastida P, Llort A, Armadans L et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologica 2003; 88: 290–299.
Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56–62.
Stevens RF, Hann IM, Wheatley K, Gray RG . Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101: 130–140.
Bleakley M, Lau L, Shaw PJ, Kaufman A . Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant 2002; 29: 843–852.
Alonzo TA, Wells RJ, Woods WG, Lange B, Gerbing RB, Buxton AB et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia 2005; 19: 965–970.
Reinhardt D, Kremens B, Zimmermann M, Vormoor J, Dworzak M, Peters C et al. No improvement of overall-survival in children with high-risk acute myeloid leukemia by stem cell transplantation in 1st complete remission. Blood 2006; 108: 99a.
Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008; 111: 1044–1053.
Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Loffler H et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104: 630–639.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.
Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 2003; 21: 2940–2947.
Aversa F, Reisner Y, Martelli MF . The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008; 40: 8–12.
Bader P, Willasch A, Niethammer D, Klingebiel T . Haploidentical stem cell transplantation in childhood. Current Cancer Therapy Reviews 2007; 3: 37–44.
Michel G, Rocha V, Chevret S, Arcese W, Chan KW, Filipovich A et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group Analysis. Blood 2003; 102: 4290–4297.
Creutzig U, Reinhardt D, Zimmermann M, Klingebiel T, Gadner H . Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: a matter of controversies. Blood 2001; 97: 3671–3672; author reply 3674-3675.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Klingebiel, T., Reinhardt, D., Bader, P. et al. Place of HSCT in treatment of childhood AML. Bone Marrow Transplant 42 (Suppl 2), S7–S9 (2008). https://doi.org/10.1038/bmt.2008.276
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.276
Keywords
This article is cited by
-
Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire
Bone Marrow Transplantation (2014)
-
Development of treatment and clinical results in childhood acute myeloid leukemia in Poland
memo - Magazine of European Medical Oncology (2013)
-
Access to allogeneic hematopoietic SCT for patients with MDS or relapsed AML treated according to protocols of the Dutch Childhood Oncology Group
Bone Marrow Transplantation (2012)